ClinicalTrials.gg
CompletedNCT07947277TFERCC_KCRBUpdated Nov 18, 2026

First-Line Nivolumab Plus Ipilimumab or Cabozantinib Followed by Second-Line Lenvatinib Plus Everolimus in Metastatic TFE-Rearranged Renal Cell Carcinoma

A Phase 2 interventional study of Nivolumab (3mg/kg) and Ipilimumab (1mg/kg) in TFE3-Rearranged Renal Cell Carcinoma, sponsored by Kidney Cancer Research Bureau. Completed at 5 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Kidney Cancer Research Bureau · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 9 months after the study started (first participant enrolled Feb 2024, registered Nov 2026).
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 64 studies testing nivolumab in Carcinoma, Renal Cell — 9 open to participants now, 23 under way, 3 of them phase 3. Nivolumab · Carcinoma, Renal Cell.

Enrollment
51st of 64
12 · median 52
Started
2024
with 4 others
Phase 2
36 of 64
6 open now
Registered
64th of 64
by date
Lead sponsor
2 of 64
Kidney Cancer Research Bureau

Among the 64 studies testing nivolumab in Carcinoma, Renal Cell, this one is the 51st largest by enrollment, is one of 5 that started in 2024, is one of 36 in phase 2, and was the 64th registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 397 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

9 of the 64 studies testing nivolumab in Carcinoma, Renal Cell are open now, in 7 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing nivolumab in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

This randomized phase 2 study evaluates the efficacy and safety of nivolumab plus ipilimumab versus nivolumab plus cabozantinib as first-line treatment in patients with metastatic TFE-rearranged renal cell carcinoma. Patients are randomly assigned to one of the two treatment groups. Following disease progression, patients receive protocol-specified second-line treatment with lenvatinib plus everolimus. The study assesses treatment outcomes during first-line therapy and across the planned treatment sequence.

Read the detailed description

This prospective, randomized phase 2 pilot study evaluates two first-line nivolumab-based combinations followed by protocol-specified second-line lenvatinib plus everolimus in patients with metastatic TFE-rearranged renal cell carcinoma (RCC). The study assesses the activity and safety of each first-line regimen and explores outcomes across the planned treatment sequence.

Eligible patients have histologically confirmed metastatic TFE-rearranged RCC, with diagnostic confirmation by immunohistochemistry and/or fluorescence in situ hybridization, and no prior systemic therapy for metastatic disease. Additional eligibility criteria include an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 and intermediate- or poor-risk disease according to International Metastatic RCC Database Consortium (IMDC) criteria.

The study includes 12 patients randomly assigned in a 1:1 ratio to nivolumab plus ipilimumab or nivolumab plus cabozantinib, with six patients in each arm. Treatment is administered at standard doses and schedules for metastatic RCC and continues until disease progression or unacceptable toxicity. Upon progression, eligible patients are offered protocol-specified second-line lenvatinib plus everolimus, regardless of their initial treatment assignment. Computed tomography assessments are performed every 12 weeks.

The primary endpoint is investigator-assessed objective response rate during first-line treatment, evaluated separately in each randomized arm. Secondary endpoints include first-line progression-free survival, second-line objective response rate and progression-free survival, duration of response in both treatment lines, overall survival, and the incidence of grade 3 or higher treatment-related adverse events. Overall survival is measured from the initiation of first-line treatment to death from any cause.

The study uses a signal-seeking design in which each first-line arm is assessed independently against a prespecified null objective response rate of 5%. At least two objective responses among six patients constitute a positive activity signal. Response rates are reported with exact two-sided 95% confidence intervals, and time-to-event outcomes are analyzed descriptively. The study is not powered for formal between-arm comparisons.

03

Conditions studied

  • TFE3-Rearranged Renal Cell Carcinoma

Keywords

  • Translocation renal cell carcinoma
  • TFE3
  • TFEB
  • Nivolumab plus Ipilimumab
  • Nivolumab plus Cabozantinib
  • Lenvatinib plus Everolimus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed TFE-rearranged renal cell carcinoma, supported by immunohistochemistry and/or fluorescence in situ hybridization.
  • No prior systemic therapy for metastatic disease.
  • performance status of 0-1.
  • Intermediate- or poor-risk disease according to IMDC criteria.
  • according to version 1.1.
  • Adequate bone marrow, hepatic, and renal function.
  • Written .

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled or symptomatic central nervous system or .
  • Active disease requiring systemic treatment.
  • Requirement for chronic systemic immunosuppression, excluding physiological replacement.
  • Uncontrolled hypertension or uncontrolled cardiovascular disease.
  • Active infection requiring systemic treatment.
  • Active clinically significant bleeding.
  • Current pneumonitis or interstitial lung disease.
  • Major surgery without adequate postoperative recovery.
  • Known severe to any component of the assigned study treatment.
  • Pregnancy or breastfeeding.
  • Any condition that, in the investigator's judgment, compromises patient safety or adherence to study procedures.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    nivolumab plus ipilimumab

    nivolumab plus ipilimumab

    Drug: Nivolumab (3mg/kg) · Drug: Ipilimumab (1mg/kg)

  • Experimental
    nivolumab plus cabozantinib

    nivolumab plus cabozantinib

    Drug: Nivolumab (3mg/kg) · Drug: Cabozantinib 60 MG

  • Experimental
    lenvatinib plus everolimus

    lenvatinib plus everolimus

    Drug: Lenvatinib 18 MG · Drug: Everolimus 5 MG

Interventions

06

What researchers measure

Primary outcomes

  1. First-Line Objective Response Rate (ORR)

    The proportion of patients achieving a complete or partial response during first-line treatment, as assessed by the investigator according to RECIST version 1.1. ORR is evaluated separately in each randomized arm.

    Time frame: 12 months

Secondary outcomes

  1. First-Line Progression-Free Survival (PFS)

    Time from initiation of first-line treatment to the first documented disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first.

    Time frame: 24 months

  2. Second-Line ORR

    The proportion of patients receiving second-line lenvatinib plus everolimus who achieve a complete or partial response, as assessed by the investigator according to RECIST version 1.1.

    Time frame: 6 months

  3. Second-Line PFS

    Time from initiation of second-line lenvatinib plus everolimus to the first documented disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first.

    Time frame: 12 months

  4. Duration of Response (DoR)

    Time from the first documented complete or partial response to disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first.

    Time frame: 24 months

  5. Overall Survival

    Time from initiation of first-line treatment to death from any cause.

    Time frame: 24 months

  6. Incidence of Grade 3 or Higher Treatment-Related Adverse Events

    The proportion of patients experiencing at least one grade 3 or higher treatment-related adverse event, graded according to NCI CTCAE version 5.0.

    Time frame: 24 months

07

Study locations

5 sites
  • BUCARE
    New York, New York 10032, United States
  • Asfendiyarov Kazakh National Medical University
    Almaty, Kazakhstan
  • Dr. Sergey Berezin Medical Institute
    Saint Petersburg, Russia
  • Yaroslavl regional cancer center
    Yaroslavl, Russia
  • Etlik City Hospital
    Ankara, Turkey (Türkiye)
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Oct 2026, 32 months.

Of 185 non-industry phase 2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 98. This study's 32 months is below that.

Counting every sponsor, half of 232 studies reached it within 58 months; a quarter within 33 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartActual
Feb 5, 2024
Primary completionActual
Oct 12, 2026
CompletionActual
Nov 12, 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07947277
Lead sponsor
Kidney Cancer Research Bureau
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Feb 5, 2024
Primary completion
Oct 12, 2026
Completion
Nov 12, 2026
Last update
Nov 18, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Ipilimumab · Cabozantinib · Everolimus

Start the discussion